comparemela.com

Latest Breaking News On - Taylor schreiber - Page 2 : comparemela.com

Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

- Announced positive topline data from the ongoing Phase 1A/B clinical trial of SL-172154 in combination with azacitidine (AZA) in frontline Highe.

United statesNorth carolinaConor richardsonMirvetuximab soravtansineTaylor schreiberAmerican society of hematologyExchange commissionShattuck labs incCancer researchOno pharmaceutical co ltdHealth care conference bostonDevelopment rd expensesRna work in cancer researchHigher risk myelodysplastic syndromesAcute myeloid leukemiaAmerican society

Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

- Announced positive topline data from the ongoing Phase 1A/B clinical trial of SL-172154 in combination with azacitidine in frontline Higher-Risk Myelodysplastic Syndromes and frontline TP53 mutant.

United statesNorth carolinaTaylor schreiberConor richardsonMirvetuximab soravtansineCancer researchRna work in cancer researchShattuck labs incOno pharmaceutical co ltdExchange commissionDevelopment rd expensesHealth care conference bostonAmerican society of hematologyHigher risk myelodysplastic syndromesAcute myeloid leukemiaAmerican society

Ono Enters into a Drug Discovery Collaboration and Option Agreement with Shattuck Labs to Generate Bifunctional Fusion Proteins

/PRNewswire/ Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; "Ono") today announced that it has entered into a drug discovery.

United statesNorth carolinaTaylor schreiberToichi takinoGyo sagaraDiscovery research of onoPrnewswire ono pharmaceutical co ltdShattuck labs incShattuck labsSenior executive officerExecutive directorOno pharmaceuticalChief executive officerAgonist redirected checkpointOno pharmaceutical co

Shattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases

AUSTIN, TX and DURHAM, NC, Feb. 13, 2024 Shattuck Labs, Inc. , a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic.

North carolinaUnited statesTaylor schreiberConor richardsonToichi takinoOno pharmaceutical co ltdDiscovery research of onoShattuck labs incExchange commissionOno pharmaceuticalChief executive officerSenior executiveExecutive directorShattuck labsAgonist redirected checkpointAnnual report

Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2024

AUSTIN, TX and DURHAM, NC, Jan. 08, 2024 Shattuck Labs, Inc. , a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic.

United statesNorth carolinaSan franciscoConor richardsonTaylor schreiberExchange commissionAmerican society of clinical oncologyShattuck labs incAmerican society of hematology annual meetingChief executive officerResistant ovarian cancerAmerican societyClinical oncologyRisk myelodysplastic syndromesAcute myeloid leukemiaHematology annual

vimarsana © 2020. All Rights Reserved.